Valerio Therapeutics (FRA:C4X) Change In Receivables : €0.00 Mil (TTM As of Jun. 2024)

View and export this data going back to . Start your Free Trial

What is Valerio Therapeutics Change In Receivables?

Valerio Therapeutics's change in receivables for the quarter that ended in Jun. 2024 was €0.00 Mil. It means Valerio Therapeutics's Accounts Receivable stayed the same from Dec. 2023 to Jun. 2024 .

Valerio Therapeutics's change in receivables for the fiscal year that ended in Dec. 2023 was €0.00 Mil. It means Valerio Therapeutics's Accounts Receivable stayed the same from Dec. 2022 to Dec. 2023 .

Valerio Therapeutics's Accounts Receivable for the quarter that ended in Jun. 2024 was €0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Valerio Therapeutics's Days Sales Outstanding for the six months ended in Jun. 2024 was 0.00.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Valerio Therapeutics's liquidation value for the six months ended in Jun. 2024 was €-21.32 Mil.

Valerio Therapeutics Change In Receivables Historical Data

The historical data trend for Valerio Therapeutics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Valerio Therapeutics Change In Receivables Chart

Valerio Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

Valerio Therapeutics Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

Valerio Therapeutics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

Valerio Therapeutics (FRA:C4X) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Valerio Therapeutics's Days Sales Outstanding for the quarter that ended in Jun. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0.089	*	91
=	0.00

2. In Ben Graham's calculation of liquidation value, Valerio Therapeutics's accounts receivable are only considered to be worth 75% of book value:

Valerio Therapeutics's liquidation value for the quarter that ended in Jun. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	4.003	-	25.319	+	0.75 * 0	+	0.5 * 0
=	-21.32

Valerio Therapeutics Change In Receivables Related Terms

Thank you for viewing the detailed overview of Valerio Therapeutics's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Valerio Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Valerio Therapeutics (FRA:C4X) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

ALVIO:France

Address

49 Boulevard du General, Martial Valin, Paris, FRA, 75015

Website

https://www.valeriotx.com

Valerio Therapeutics is a clinical-stage biotechnology company designing and developing novel oncology drugs targeting tumor DNA repair functions. Its therapeutic strategy focuses on fighting tumor resistance to treatments, which poses ever-greater therapeutic challenges, especially in aggressive or rare cancers. its approach is based upon unique mechanisms of action on DNA Damage Response. The company focuses on bringing first-in-class and disruptive compounds from preclinical research to proof-of-concept in man in cancer indications with high unmet needs.

Valerio Therapeutics Headlines

No Headlines